Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Angelalign TechnologyFRA:77D -3.09%75 Equity-to-Asset is 0.52 as of Jun. 2026, which is 24% below its 10-year median of 0.68. GuruFocus rates FRA:77D with a GF Score™ of 75/100 and a GF Value™ of €11.54 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Angelalign Technology ranks worse than 64.16% on this metric.
The historical rank and industry rank for Angelalign Technology's Equity-to-Asset or its related term are showing as below:
FRA:77D'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35 Med: 0.68 Max: 0.8
Current: 0.52
During the past 8 years, the highest Equity to Asset Ratio of Angelalign Technology was 0.80. The lowest was 0.35. And the median was 0.68.
FRA:77D's Equity-to-Asset is ranked worse than 64.16% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs FRA:77D: 0.52
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Angelalign Technology Equity-to-Asset Related Terms
Angelalign Technology Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Angelalign Technology's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:77D vs ISRG, BDX, RMD: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Angelalign Technology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Angelalign Technology Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Angelalign Technology's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Angelalign Technology's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Angelalign Technology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Angelalign Technology (FRA:77D) has a Equity-to-Asset of 0.52 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Angelalign Technology and its competitors. This is 24% below median its historical median of 0.68. Over the past decade, Angelalign Technology's Equity-to-Asset has ranged from 0.35 to 0.80. According to the industry distribution chart, Angelalign Technology ranks #546 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 64.2%.
Is Angelalign Technology's Equity-to-Asset too high?
Angelalign Technology's current Equity-to-Asset of 0.52 is 24% below median its 10-year median of 0.68. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.80. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Angelalign Technology's value of 0.52 is 18.8% below this industry median. Based on the distribution chart, Angelalign Technology ranks #546 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Angelalign Technology has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Angelalign Technology's Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Angelalign Technology ranks #546 out of 851 companies for Equity-to-Asset. This places Angelalign Technology in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Angelalign Technology's value of 0.52 is 18.8% below this benchmark. Historically, Angelalign Technology's own Equity-to-Asset has ranged from 0.35 to 0.80 over the past decade. While the company's 10-year median is 0.68 vs. the industry median of 0.64, Angelalign Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Angelalign Technology's current Equity-to-Asset of 0.52 is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Angelalign Technology and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Angelalign Technology's current Equity-to-Asset is 0.52, which is 24% below median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angelalign Technology stock overvalued right now?
Based on GuruFocus' analysis, Angelalign Technology (FRA:77D) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.54, compared to a current price of €9.40 — trading 18.5% below its estimated fair value. The current Equity-to-Asset is 0.52, which is 24% below median its 10-year median of 0.68 and 18.8% below the Medical Devices & Instruments industry median of 0.64. Angelalign Technology's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Angelalign Technology (FRA:77D), the current Equity-to-Asset is 0.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Angelalign Technology (FRA:77D) Overvalued in 2026?
Based on GuruFocus' analysis, Angelalign Technology stock appears to be undervalued.
The current stock price of €9.40 is trading 18.5% below its estimated GF Value™ of €11.54.
GuruFocus considers Angelalign Technology to be Modestly Undervalued.
Key valuation signals for FRA:77D:
Equity-to-Asset: 0.52 (24% below median its 10-year median of 0.68)
GF Value™: €11.54 vs. price of €9.40 (18.5% below fair value)
Industry Position: 18.8% below the Medical Devices & Instruments median (#546 of 851)
No single metric tells the full story. See the FRA:77D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions, including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontic solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review, and modify treatment plans.
75GF Score
Get the complete analysis for FRA:77D
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:77D has been successfully added to your 
